Lexeo Therapeutics (LXEO) said Wednesday it has seen "positive" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.
Treatment with the gene therapy candidate resulted in "dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes," the company said.
The candidate drug also showed a "favorable safety profile," the company said.
Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.
The company's shares fell nearly 10% in recent trading.
Price: 8.98, Change: -0.99, Percent Change: -9.93
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。